Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Rita R. Kalyani
Abstract
In patients with type 2 diabetes and established cardiovascular disease (or in those with a high risk of cardiovascular disease) in whom glycemic goals are not achieved with metformin, agents from the GLP-1 receptor agonist or SGLT2 inhibitor classes with demonstrated cardiovascular benefit constitute the recommended treatment.
Topics & Concepts
MetforminType 2 diabetesMedicineDiabetes mellitusDiseaseGlycemicAgonistInternal medicinePharmacologyEndocrinologyReceptorDiabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment